Multiple endocrine neoplasia type 1 laboratory findings
Multiple endocrine neoplasia type 1 Microchapters |
Differentiating Multiple endocrine neoplasia type 1 from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Multiple endocrine neoplasia type 1 laboratory findings On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 laboratory findings |
FDA on Multiple endocrine neoplasia type 1 laboratory findings |
CDC on Multiple endocrine neoplasia type 1 laboratory findings |
Multiple endocrine neoplasia type 1 laboratory findings in the news |
Blogs on Multiple endocrine neoplasia type 1 laboratory findings |
Directions to Hospitals Treating Multiple endocrine neoplasia type 1 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 1 laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [3]
Overview
Laboratory findings consistent with the diagnosis of multiple endocrine neoplasia type 1 include increased parathyroid hormone, increased gastrin concentration, and increased cortisol concentration.
Laboratory Findings
Laboratory tests may be performed periodically to screen for multiple endocrine neoplasia type 1 tumors[1][2][3][4]
Blood Tests
Urine Tests
Urinary calcium to detect the results of excess hormone production
References
- ↑ [1] MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1 NCI
- ↑ Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML (2012). "Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)". J. Clin. Endocrinol. Metab. 97 (9): 2990–3011. doi:10.1210/jc.2012-1230. PMID 22723327.
- ↑ Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, Rao DS, Rubin MR, Goltzman D, Silverberg SJ, Marx SJ, Peacock M, Mosekilde L, Bouillon R, Lewiecki EM (2009). "Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop". J. Clin. Endocrinol. Metab. 94 (2): 340–50. doi:10.1210/jc.2008-1758. PMID 19193909.
- ↑ Skandarajah A, Barlier A, Morlet-Barlat N, Sebag F, Enjalbert A, Conte-Devolx B, Henry JF, Makar AB, McMartin KE, Palese M, Tephly TR, Roskoski R, Lim CT, Roskoski LM, Warth J, Desforges JF, Chow YW, Pietranico R, Mukerji A, Kienia AI, Moroi K, Sato T, Schwabbauer ML, Skandarajah A, Barlier A, Morlet-Barlat N, Sebag F, Enjalbert A, Conte-Devolx B, Henry JF, Schmoldt A, Benthe HF, Haberland G, Mills GC, Alperin JB, Trimmer KB, Moore G, Burford G, Lederis K, Marniemi J, Parkki MG, Nilsson SF, Peterson PA, Hendrickson WA, Ward KB (2010). "Should routine analysis of the MEN1 gene be performed in all patients with primary hyperparathyroidism under 40 years of age?". World J Surg. 34 (6): 1294–8. doi:10.1007/s00268-009-0388-5. PMID 20058152.